Skeletal Muscle Relaxants

The name "muscle relaxant" hides two very different clinical problems. Antispasmodics treat acute, painful muscle spasm — the classic thrown-out-back strain — as a short-term adjunct to rest and physical therapy. Antispastics treat spasticity, the chronic, velocity-dependent stiffness that comes from an upper-motor-neuron injury — multiple sclerosis, cerebral palsy, spinal-cord injury, stroke — where the goal is ongoing function, not a two-week course. Sorting a drug into the right family tells you how it’s used and how long.

An important mechanistic point about the antispasmodics: most of them don’t act on muscle at all. Cyclobenzaprine, methocarbamol, carisoprodol, and metaxalone are central nervous system depressants whose "relaxation" is largely generalized sedation damping down spinal reflex activity — their exact mechanisms are poorly defined. Cyclobenzaprine is even structurally a tricyclic antidepressant, which is why it carries anticholinergic baggage. The antispastics are more targeted: baclofen is a GABA-B agonist in the spinal cord; diazepam works through GABA-A; tizanidine is a central alpha-2 agonist (like clonidine). And one drug stands apart entirely — dantrolene — which we’ll come to.

Because so many of these drugs work by sedating the brain, the defining class effect is exactly that: drowsiness, dizziness, and weakness — a direct fall risk, especially in older adults (the AGS Beers Criteria, as reported by StatPearls, list skeletal muscle relaxants among medications to avoid in adults older than 65, citing anticholinergic effects, sedation, falls, and fractures). This is why they are meant for short-term use (cyclobenzaprine only 2–3 weeks), why patients are told not to drive until they know the effect, and why fall precautions are routine.

A central safety concept is additive CNS depression. Stack a muscle relaxant on top of an opioid, a benzodiazepine, or alcohol, and the sedation compounds — the FDA warns this combination can cause profound sedation, respiratory depression, and death. The muscle relaxant isn’t usually the headline drug in that warning, but muscle relaxants are among the CNS depressants it names. So the nurse’s reflex is to scan the whole medication list for other depressants before giving one, and to teach patients not to add alcohol. One agent raises the stakes further: carisoprodol (Soma) is metabolized to meprobamate and is a Schedule IV controlled substance with real abuse, dependence, and withdrawal potential.

Beyond the shared sedation, several agents carry specific dangers worth memorizing. Cyclobenzaprine, being a tricyclic, brings anticholinergic effects (dry mouth, urinary retention, blurred vision) and is contraindicated within 14 days of an MAO inhibitor (hyperpyretic crisis, seizures, death), in the acute recovery phase of MI, and with arrhythmias/heart block or hyperthyroidism. Tizanidine can drop blood pressure (alpha-2 agonist), needs liver-enzyme monitoring, and is contraindicated with the CYP1A2 inhibitors ciprofloxacin and fluvoxamine, which raise its level enormously (about 33-fold with fluvoxamine) → dangerous hypotension and sedation. Baclofen must never be stopped abruptly — and intrathecal baclofen (delivered by an implanted pump) carries a boxed warning: sudden withdrawal (a failed pump, empty reservoir) causes high fever, altered mental status, and rebound spasticity that can progress to rhabdomyolysis, multi-organ failure, and death — a true emergency.

Then there is dantrolene, the exception that proves the rule. Unlike every other agent here, it acts directly on skeletal muscle, blocking the ryanodine receptor so the sarcoplasmic reticulum releases less calcium — it uncouples excitation from contraction rather than acting through the brain (although drowsiness is still its most frequent side effect). That unique action makes it the specific antidote for malignant hyperthermia (the runaway hypermetabolic crisis triggered by certain anesthetics) and useful in neuroleptic malignant syndrome. Its price is the liver: oral dantrolene carries a boxed warning for hepatotoxicity, so liver function is checked before and during therapy. (Tizanidine and metaxalone also warrant liver awareness.)